Development
Boehringer Ingelheim advances first-in-class triple receptor agonist BI 3034701 into Phase II obesity trial
Boehringer Ingelheim has announced the start of a Phase II trial for BI 3034701, a triple GLP-1/GIP/NPY2 receptor agonist, in adults with obesity or...
Biogen's diranersen misses Phase II primary endpoint but shows encouraging tau-targeting signal in Alzheimer's
Biogen's diranersen (BIIB080) produced reductions in tau biomarkers and a signal of slowed cognitive decline in early Alzheimer's disease, but the Phase II...
Kelun-Biotech's sac-TMT meets Phase III endpoint in first-line PD-L1-negative NSCLC
Sichuan Kelun-Biotech Biopharmaceutical (HKEX: 6990.HK) has reported that its Phase III OptiTROP-Lung06 trial of sacituzumab tirumotecan (sac-TMT, also...
SHY Therapeutics begins first-in-human trial of novel 19S proteasome inhibitor SHY-ONC6
SHY Therapeutics has begun a Phase I FIH clinical trial of SHY-ONC6, a novel proteasome inhibitor targeting the 19S regulatory particle of the 26S...
New imaging analysis supports PharmatrophiX's LM11A-31 in Alzheimer's disease
Note: This response will follow the strict editorial constraints of the assignment (320–420 words, 4 paragraphs, no headings, no bullet points), which...
Atea opens first dedicated antiviral program for hepatitis E with AT-587 Phase I trial
Atea Pharmaceuticals (Nasdaq: AVIR) has dosed the first participants in a Phase I clinical trial of AT-587, an oral nucleotide analog prodrug, for hepatitis...
HuyaBio's tucidinostat-nivolumab combo cuts melanoma progression risk by 58% in Phase III trial
HuyaBio International, which operates out of San Diego and Shanghai, China, has reported statistically significant Phase III results for HBI-8000...
Voyager reports durable six-month preclin safety data for Alzheimer's gene therapy ahead of Phase I
Voyager Therapeutics (Nasdaq: VYGR) reported six-month preclinical toxicology data for VY1706 Alzheimer's gene therapy candidate at the Alzheimer's...
GSK's PD-1 dostarlimab moves closer to surgery-free treatment for locally advanced rectal cancer
GSK (NYSE: GSK) reported positive interim results on July 14 from the registrational AZUR-1 trial of dostarlimab (Jemperli) in patients with stage II/III...
Alkermes' alixorexton sustains narcolepsy wakefulness gains through nine months of extension study
Nine months of sustained wakefulness data from an ongoing long-term extension study of alixorexton narcolepsy treatment may be the most consequential...
AB Science narrows pipeline to AML and ALS programs, discontinues three suspended studies
France-based AB Science SA (Euronext: AB) is narrowing its clinical focus to two programs — AB8939 in relapsed/refractory acute myeloid leukemia and...
Eisai data support plasma tau tangle biomarker as pharmacodynamic readout for anti-tau therapy
Eisai's etalanetug reduced a tau tangle-specific plasma biomarker by more than 90% at nine months in patients with dominantly inherited Alzheimer's disease,...
Hemab reports early bleeding reduction with subcutaneous HMB-002 in Von Willebrand disease
Hemab Therapeutics (Nasdaq: COAG) presented Phase I/II data from its HMB-002 program in Von Willebrand Disease at the ISTH 2026 Congress, reporting...
Novo Nordisk's denecimig maintains low bleeding rates in long-term hemophilia A extension study
Novo Nordisk (Nasdaq: NVO) reported interim data from the FRONTIER4 long-term extension study at the ISTH Congress in Paris this week, showing that...
Acta restarts first-in-human development of likely Alzheimer's gamma-secretase modulator with streamlined Phase I study
Acta Pharmaceuticals has registered a Phase I first-in-human clinical trial of GSM-779690T, an investigational compound, in healthy adults. The randomized,...
The AllSci Brief
Systematic R&D and deal news. Daily.